Maravai Lifesciences Holdings (MRVI) Cash & Equivalents (2022 - 2026)

Maravai Lifesciences Holdings' Cash & Equivalents history runs 5 years deep, the most recent figure standing at $165.9 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 41.79% year-over-year to $165.9 million; the TTM figure through Mar 2026 stood at $165.9 million (down 41.79% YoY), while the FY2025 annual figure was $216.9 million, down 32.73% from the prior year.
• Cash & Equivalents was $165.9 million for Q1 2026 at Maravai Lifesciences Holdings, down from $216.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $632.1 million in Q4 2022 to a low of $165.9 million in Q1 2026.
• Historically, Cash & Equivalents has averaged $429.5 million across 5 years, with a median of $561.7 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents decreased 0.25% in 2024, then slumped 57.87% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $632.1 million in 2022, then slipped by 9.04% to $575.0 million in 2023, then sank by 43.93% to $322.4 million in 2024, then plunged by 32.73% to $216.9 million in 2025, then declined by 23.5% to $165.9 million in 2026.
• The last three Cash & Equivalents figures came in at $165.9 million (Q1 2026), $216.9 million (Q4 2025), and $243.6 million (Q3 2025), per Business Quant data.